Unveiling a Biomarker Signature of Meningioma: The Need for a Panel of Genomic, Epigenetic, Proteomic, and RNA Biomarkers to Advance Diagnosis and Prognosis

Unveiling a Biomarker Signature of Meningioma: The Need for a Panel of Genomic, Epigenetic, Proteomic, and RNA Biomarkers to Advance Diagnosis and Prognosis

Meningiomas are the most prevalent primary intracranial tumors. The majority are benign but can undergo dedifferentiation into advanced grades classified by World Health Organization (WHO) into Grades 1 to 3. Meningiomas’ tremendous variability in tumor behavior and slow growth rates complicate thei...

Full description

Bibliographic Details
Main Authors: Reem Halabi, Fatima Dakroub, Mohammad Z. Haider, Stuti Patel, Nayef A. Amhaz, Mohammad A. Reslan, Ali H. Eid, Yehia Mechref, Nadine Darwiche, Firas Kobeissy, Ibrahim Omeis, Abdullah A. Shaito
Format: Article
Language:English
Published: MDPI AG 2023-11-01
Series:Cancers
Subjects:
meningioma
<i>NF2</i> mutations
biomarker
miRNA
proteomics
Online Access:https://www.mdpi.com/2072-6694/15/22/5339

Internet

https://www.mdpi.com/2072-6694/15/22/5339

Similar Items